Lars Søndergaard1, Josep Rodés-Cabau2, Axel Hans-Peter Linke3, Stephan Fichtlscherer4, Ulrich Schäfer5, Karl-Heinz Kuck6, Joerg Kempfert7, Dabit Arzamendi8, Francesco Bedogni9, Federico M Asch10, Stephen Worthley11, Francesco Maisano12. 1. Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Electronic address: Lars.Soendergaard.01@regionh.dk. 2. Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. 3. Technical University Dresden, Heart Center Dresden, Dresden, Germany. 4. Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany. 5. UKE Hamburg (Universitatsklinik Eppendorf), Hamburg, Germany. 6. Asklepios Klinik St. Georg, Lohmuehlenstrasse, Hamburg, Germany. 7. Deutsches Herzzentrum Berlin, Berlin, Germany. 8. Hospital de la Santa Creu I Sant Pau, Sant Antoni Maria Claret, Barcelona, Spain. 9. IRCCS Policlinico San Donato, Piazza E. Malan, San Donato Milanese, Italy. 10. Cardiovascular Core Laboratories, MedStar Health Research Institute at Washington Hospital Center, Washington, DC. 11. Royal Adelaide Hospital, Adelaide, South Australia, Australia. 12. Clinic for Heart and Vascular Surgery, University Hospital Zurich, Zurich, Switzerland.
Abstract
BACKGROUND: The new self-expanding, repositionable transcatheter heart valve (THV) system was designed for treatment of severe, symptomatic aortic stenosis in patients with high surgical risk. OBJECTIVES: The purpose of this study was to report 1-year outcomes of transcatheter aortic valve replacement with the new THV system. METHODS: This ongoing, international, multicenter study evaluated patients with severe, symptomatic aortic stenosis implanted with the THV via transfemoral access and follow-up at 30 days, 1 year, and annually through 5 years. The primary endpoint is all-cause mortality at 1 year; secondary endpoints include clinical outcomes and echocardiographic measurements, both adjudicated. RESULTS: A total of 941 patients (82.4 ± 5.9 years; 65.7% female; Society of Thoracic Surgeons Predicted Risk of Operative Mortality score: 5.8%) were enrolled and underwent an implant at 61 sites in Europe, Australia, and Canada. At 1 year, Kaplan-Meier estimates for all-cause mortality, cardiovascular mortality, disabling stroke rates, and myocardial infarction were 12.1%, 6.6%, 2.2%, and 2.5%, respectively. Mean aortic transvalvular gradient and aortic valve area were 8.66 mm Hg and 1.75 cm2, respectively. Paravalvular leakage was moderate or higher in 2.6% of patients with no severe leakage. New pacemaker rates were 18.7% and 21.3% for pacemaker naïve patients at 30 days and 1 year, respectively. Functional class, exercise capacity, and quality of life improved significantly from baseline to 1 year. CONCLUSIONS: Transcatheter aortic valve replacement with the new THV in patients who are at increased surgical risk is associated with low 1-year mortality and stroke rates. Favorable hemodynamic results at 1 year are observed with low transvalvular pressure gradient and incidence of significant paravalvular leakage. (5 Year Observation of Patients With PORTICO Valves [PORTICO-I]; NCT01802788).
BACKGROUND: The new self-expanding, repositionable transcatheter heart valve (THV) system was designed for treatment of severe, symptomatic aortic stenosis in patients with high surgical risk. OBJECTIVES: The purpose of this study was to report 1-year outcomes of transcatheter aortic valve replacement with the new THV system. METHODS: This ongoing, international, multicenter study evaluated patients with severe, symptomatic aortic stenosis implanted with the THV via transfemoral access and follow-up at 30 days, 1 year, and annually through 5 years. The primary endpoint is all-cause mortality at 1 year; secondary endpoints include clinical outcomes and echocardiographic measurements, both adjudicated. RESULTS: A total of 941 patients (82.4 ± 5.9 years; 65.7% female; Society of Thoracic Surgeons Predicted Risk of Operative Mortality score: 5.8%) were enrolled and underwent an implant at 61 sites in Europe, Australia, and Canada. At 1 year, Kaplan-Meier estimates for all-cause mortality, cardiovascular mortality, disabling stroke rates, and myocardial infarction were 12.1%, 6.6%, 2.2%, and 2.5%, respectively. Mean aortic transvalvular gradient and aortic valve area were 8.66 mm Hg and 1.75 cm2, respectively. Paravalvular leakage was moderate or higher in 2.6% of patients with no severe leakage. New pacemaker rates were 18.7% and 21.3% for pacemaker naïve patients at 30 days and 1 year, respectively. Functional class, exercise capacity, and quality of life improved significantly from baseline to 1 year. CONCLUSIONS: Transcatheter aortic valve replacement with the new THV in patients who are at increased surgical risk is associated with low 1-year mortality and stroke rates. Favorable hemodynamic results at 1 year are observed with low transvalvular pressure gradient and incidence of significant paravalvular leakage. (5 Year Observation of Patients With PORTICO Valves [PORTICO-I]; NCT01802788).
Authors: Francesco Moroni; Lorenzo Azzalini; Lars Sondergaard; Guilherme F Attizzani; Santiago García; Hani Jneid; Mamas A Mamas; Rodrigo Bagur Journal: J Am Heart Assoc Date: 2022-06-14 Impact factor: 6.106
Authors: Costanza Pellegrini; Tobias Rheude; Jonathan Michel; Hector A Alvarez-Covarrubias; Sarah Wünsch; N Patrick Mayr; Erion Xhepa; Adnan Kastrati; Heribert Schunkert; Michael Joner; Markus Kasel Journal: J Thorac Dis Date: 2020-11 Impact factor: 2.895
Authors: Fernando L M Bernardi; Josep Rodés-Cabau; Gabriela Tirado-Conte; Ignacio J Amat Santos; Claudia Plachtzik; Fernando Cura; Matias Sztejfman; Fernanda M Mangione; Rogério Tumeleiro; Vinicius Borges Cardozo Esteves; Eduardo França Pessoa de Melo; Alejandro Alcocer Chauvet; Felipe Fuchs; Rogerio Sarmento-Leite; Estêvão Carvalho de Campos Martins; Luis Nombela-Franco; José Raul Delgado-Arana; Wolfgang Bocksch; Pablo Lamelas; Carlos Giuliani; Diego Carter Campanha-Borges; Jose A Mangione; Fábio Sandoli de Brito; Alexandre C Abizaid; Henrique B Ribeiro Journal: J Am Heart Assoc Date: 2021-09-03 Impact factor: 5.501
Authors: Helge Mollmann; Axel Linke; Luis Nombela-Franco; Martin Sluka; Juan Francisco Oteo Dominguez; Matteo Montorfano; Won-Keun Kim; Martin Arnold; Mariuca Vasa-Nicotera; Lenard Conradi; Anthony Camuglia; Francesco Bedogni; Ganesh Manoharan Journal: J Clin Med Date: 2022-08-18 Impact factor: 4.964
Authors: Luigi Biasco; Enrico Cerrato; Gregorio Tersalvi; Giovanni Pedrazzini; Ben Wilkins; Francesco Faletra; Enrico Ferrari; Stefanos Demertzis; Gaetano Senatore; Angelo Di Leo; Ferdinando Varbella; Ole De Backer; Luis Nombela Franco Journal: Front Cardiovasc Med Date: 2020-03-20
Authors: Helge Möllmann; David M Holzhey; Michael Hilker; Stefan Toggweiler; Ulrich Schäfer; Hendrik Treede; Michael Joner; Lars Søndergaard; Thomas Christen; Dominic J Allocco; Won-Keun Kim Journal: Clin Res Cardiol Date: 2021-06-20 Impact factor: 5.460